Landos Biopharma, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel, first-in-class oral therapeutics for patients with autoimmune and inflammatory diseases. The company develops several immunometabolic pathway-targeting drug candidates, including omilancor, a gut-restricted oral therapy targeting lanthionine synthetase C-like protein 2 (LANCL2); NX-13, an oral drug candidate for ulcerative colitis; and LABP-104, targeting systemic lupus erythematosus and rheumatoid arthritis. Landos leverages a proprietary artificial intelligence-based platform to identify novel immunometabolic targets and develop precision medicine therapies. The company primarily operates in the United States and has strategic partnerships to commercialize its products in Asian markets, including a significant licensing and collaboration deal with LianBio to develop and sell omilancor and NX-13 in Greater China and select Asian countries. Founded in 2014 and headquartered in Yorktown Heights, New York, Landos has advanced its clinical portfolio with key Phase 2 trials such as the NEXUS trial for NX-13 in ulcerative colitis, with topline results expected in late 2024. A major recent development is Landos Biopharma's acquisition by AbbVie, completed in May 2024, whereby AbbVie expanded its autoimmune and inflammatory disease portfolio by integrating Landos' oral immunometabolic therapies. This acquisition aligns with AbbVie's strategic emphasis on innovative therapies in immunology. Prior to the acquisition, Landos secured substantial upfront and milestone payments through its alliance with LianBio, supporting its development and commercialization efforts in Asia. The company continues to focus on its clinical pipeline with plans for global Phase 3 trials and expanding its immunology-focused therapeutic offerings under AbbVie's ownership. Landos Biopharma's core expertise lies in its unique approach to immunometabolism, offering potentially first-in-class oral treatments that modulate immune responses through metabolic pathways. Its commercial and development programs target diseases such as ulcerative colitis, Crohn's disease, systemic lupus erythematosus, and rheumatoid arthritis, primarily addressing patients with autoimmune disorders. The company's work positions it as a pioneering developer of oral immunotherapies with applications in multiple geographical markets including North America and Asia through licensing collaborations. The company's proprietary computational and experimental platform, combined with clinical-stage assets, represent significant advancements in oral autoimmune disease treatments. Its recent clinical progress, strategic collaboration agreements, and acquisition by a global biopharmaceutical leader highlight its role as an innovative entity in the biopharma industry focused on oral immunometabolic therapeutics. Landos Biopharma, Inc. operates as a wholly owned subsidiary of AbbVie following the 2024 acquisition, maintaining headquarters in Yorktown Heights, New York, and contributing to AbbVie's broader portfolio in immunology and inflammatory diseases with its pipeline of oral small molecule therapies targeting novel metabolic immune pathways. The company remains committed to advancing its clinical-stage programs and bringing new treatments to market with an emphasis on improving patient outcomes in autoimmune disease management.
AbbVie Completes Acquisition of Landos Biopharma
LANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABP
Stockholder Alert: Ademi LLP continues Investigation of the Fairness of Landos Biopharma, Inc.'s transaction with AbbVie
LANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABP
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Landos Biopharma, Inc - LABP
Why Is Landos Biopharma (LABP) Stock Up 168% Today?
Shareholder Alert: Ademi LLP investigates whether Landos Biopharma, Inc. has obtained a Fair Price in its transaction with AbbVie
LABP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Landos Biopharma, Inc. Is Fair to Shareholders
AbbVie to buy Landos to expand pipeline of immunity-related illnesses
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 Results
Landos Biopharma to Present New Data on Immunometabolism at the 19th Annual Congress of the European Crohn's and Colitis Organisation
Landos Biopharma Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn's and Colitis
Landos Biopharma Provides Company Update and Reports Third Quarter 2023 Results
Landos Biopharma to Present at the American College of Gastroenterology 2023 Annual Scientific Meeting
Landos Biopharma Announces Strategic Research Collaboration with KU Leuven and University Hospitals Leuven to Further Characterize the Effects of NX-13 on Epithelial Cells
Landos Biopharma Provides Business Update & Reports Second Quarter 2023 Results
Landos Biopharma to Present at the 2023 Jefferies Healthcare Conference
3 Top Biotech Penny Stocks Under $3 To Watch Right Now